Obesity is a serious disease condition affecting 20-25% of all adults in Western societies. Even more alarmingly is the steep increase in the frequency of obesity in children.  Since obesity is a risk factor for Type 2 Diabetes and  cardiovascular disease, earlier age of onset for disease complications will likely yield increased disease management costs.  Since susceptibility to obesity and complications is highly genetic, earlier recognition of risk is an important early step to more individualized preventive actions.

IntegraGen has worked intensively on the genetics of childhood obesity.  We have identified several genes linked to various pathways involved in the dysregulation of energy homeostasis between food intake and energy expenditure.

IntegraGen collaborates with leading clinical centers and Children’s Hospitals in Europe. We are partners in EU-sponsored projects on the interaction of genes and nutrition. IntegraGen’s commitment in this area is demonstrated by our alliance with DSM.

Dr Bernard Courtieu spoke at the 3rd Meeting of the Pharmaceutical Industry in Barcelona. Date : November 5th, 2009.

His presentation focused on new approaches and business models to innovation for biotech markets.

More information : IESE Barcelona

7-10 September 2009 : Prof. Andreas Ziegler, University of Lübeck, made a presentation on methods for Evaluating clinical validity in single affected offspring trio families. at 54. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e.V. (GMDS) conference in Essen (Germany)

>> link to abstract

>> link to GMDS conference

9 june 2009 : Bernard Courtieu, CEO of IntegraGen, attended the AMIPS* conference on "Drug development for personalised medicine". His presentation focused on biomarkers development for Neurology.

*AMIPS : Association des Médecins des Industries des Produits de Santé (French association of Medical doctors of health industry products)

link to AMIPS